6 episodes

Patients Rising brings its unique and established brand of patient advocacy to a weekly podcast, featuring honest and helpful discussion about issues impacting those with chronic illness. Executive Director Terry Wilcox hosts the show, with Robert "Dr. Bob" Goldberg, Co-Founder and Vice President of the Center for Medicine in the Public Interest.

Patients Rising Podcast Patients Rising

    • Medicine
    • 5.0, 9 Ratings

Patients Rising brings its unique and established brand of patient advocacy to a weekly podcast, featuring honest and helpful discussion about issues impacting those with chronic illness. Executive Director Terry Wilcox hosts the show, with Robert "Dr. Bob" Goldberg, Co-Founder and Vice President of the Center for Medicine in the Public Interest.

    COVID-19 Epicenters

    COVID-19 Epicenters

    As coronavirus continues to spread across New York City, other virus hot spots are emerging across the country, including Detroit and New Orleans. These epicenters are seeing a surge in coronavirus patients but lack the medical supplies and staff to combat this growing crisis. But how exactly do these coronavirus epicenters come to be? And what does this mean for immunodeficient patients living in these places? 
    This week on the Patients Rising Podcast, we have part two of Dr. Bob’s interview with Dr. Hugh Rosen, who explains how and why these COVID-19 hotspots emerge. He also discusses experimental treatments for those who have contracted the virus. 
    Hugh Rosen, M.D., Ph.D.
    Professor of Molecular Medicine at The Scripps Research Institute’s California Campus and Chairman and President of ActivX Biosciences Inc.
    Dr. Rosen has over 30 years of medical experience with a research focus on lymphocyte trafficking. His work at The Scripp’s Research Institute (TSRI) led to the development of ozanimod, which helps alleviate brain atrophy for patients with multiple sclerosis. Its benefits may also extend to those suffering from other autoimmune conditions. 
    Prior to his work at TSRI, Dr. Rosen served as the Executive Director of Immunology, Rheumatology, and Infectious Diseases at Merck Research Laboratories. He was also Chair of the Worldwide Business Strategy Team for Antibacterials and Antifungals. 
    Currently, Dr. Rosen serves on the Board of Directors at Regulus. In 2017, Dr. Rosen became the President and Chairman of ActivX Bioscience Inc., a biopharmeceutical company focused on the research and development of molecular drugs.  
    Dr. Rosen earned his M.D. from the University of Cape Town and his Ph.D. in Physiological Sciences from the University of Oxford. 
    Hosts:
    Terry Wilcox, Executive Director, Patients Rising
    Dr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.
    Kate Pecora, Field Correspondent 
    Links:
    Patients Rising Concierge 
    Need help?
    The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands. Our Navigator is an online tool that allows you to search a massive network of health related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
    Have a question or comment about the show, want to suggest a show topic or share your story as a patient correspondent?
    Drop us a line: podcast@patientsrising.org

    • 41 min
    COVID-19 Treatments

    COVID-19 Treatments

    Both the federal and state governments have begun turning to the private sector for solutions to supply tests, masks, and other necessary materials for fighting COVID-19. The private sector may also have potential coronavirus treatments, some of which are already in use for other diseases.
    On Episode 5 of the Patients Rising Podcast, we discuss the potential treatment options for COVID-19 and the other ways in which the private sector is helping to alleviate the impact of coronavirus. 
    Guests:
    Sara Goldberg
    Clinical social worker.
    Hugh Rosen, M.D., Ph.D.
    Professor of Molecular Medicine at The Scripps Research Institute’s California Campus and Chairman and President of ActivX Biosciences Inc.
    Dr. Rosen has over 30 years of medical experience with a research focus on lymphocyte trafficking. His work at The Scripp’s Research Institute (TSRI) led to the development of ozanimod, which helps alleviate brain atrophy for patients with multiple sclerosis. Its benefits may also extend to those suffering from other autoimmune conditions. 
    Prior to his work at TSRI, Dr. Rosen served as the Executive Director of Immunology, Rheumatology, and Infectious Diseases at Merck Research Laboratories. He was also Chair of the Worldwide Business Strategy Team for Antibacterials and Antifungals. 
    Currently, Dr. Rosen serves on the Board of Directors at Regulus. In 2017, Dr. Rosen became the President and Chairman of ActivX Bioscience Inc., a biopharmaceutical company focused on the research and development of molecular drugs. 
    Dr. Rosen earned his M.D. from the University of Cape Town and his Ph.D. in Physiological Sciences from the University of Oxford. 
    Hosts:
    Terry Wilcox, Executive Director, Patients Rising
    Dr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.
    Kate Pecora, Field Correspondent 
    Links:
    Patients Rising Concierge 
    Need help?
    The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands. Our Navigator is an online tool that allows you to search a massive network of health related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
    Have a question or comment about the show, want to suggest a show topic or share your story as a patient correspondent?
    Drop us a line: podcast@patientsrising.org
     

    • 31 min
    COVID-19 and Supplies

    COVID-19 and Supplies

    Fears of shortages of critical health supplies like hospital gowns, masks and drugs are a big topic on every media channel. Public health leaders are concerned about reports healthcare professionals are running short of the personal protective equipment they need. Government officials are working to address the supply chain in time, and this week President Trump invoked the Defense Production Act of 1950 to address predicted supply shortfalls. 
    On Episode 4 of the Patients Rising Podcast, we discuss how the current pandemic is putting the medical supply chain to the test and how this affects patients with chronic disease. 
    Guest:
    Marion Mass, M.D.
    Philadelphia-area pediatrician and Co-Founder and Executive VP of The Practicing Physicians of America. 
    Dr. Marion Mass has practiced pediatrics in Philadelphia for over 20 years. She also currently serves as a board member of the Bucks County Health Initiative and as a delegate to the Pennsylvania Medical Society. Dr. Mass has previously been on the board of Physicians Working Together, a grassroots advocacy group focused on educating patients on healthcare issues and empowering doctors to join the healthcare reform movement. 
    Alongside her extensive medical career, Dr. Mass has also focused on advocating for sustainability within the American healthcare system. 
    In 2017, Dr. Mass co-founded The Practicing Physicians of America, which gives physicians across America a voice in Washington, D.C., and seeks to protect the patient-physician relationship and support physician autonomy. Her focus is on drug shortages and maximizing patients’ value in the healthcare system. 
    Dr. Mass earned her M.D. from Duke University School of Medicine. 
    Hosts:
    Terry Wilcox, Executive Director, Patients Rising
    Dr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.
    Kate Pecora, Field Correspondent 
    Links:
    Alabama Rare
    National Organization for Rare Disorders
    Patients Rising Concierge 
    Need help?
    The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health related resources using your zip code for local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
    Have a question or comment about the show, want to suggest a show topic or share your story as a patient correspondent?
    Drop us a line: podcast@patientsrising.org

    • 46 min
    Coronavirus and Chronic Disease

    Coronavirus and Chronic Disease

    What does coronavirus spread across the country mean for the 10 million Americans who are immuno-deficient? While COVID-19 poses a risk for the elderly, it is also concerning for Americans suffering from underlying chronic health illnesses, such as diabetes, high blood pressure, and cardiovascular disease and those in treatment for cancer. 
    On this episode of the Patients Rising Podcast, we break down what the risk of coronavirus means for these patients and their caregivers, and what precautionary resources and steps should be considered. 
    Guest:
    Paul Offit, M.D., Professor of Pediatrics and Director of Infectious Diseases at The Children’s Hospital of Philadelphia. 
    He has worked at the Children’s Hospital of Philadelphia for over 20 years, where he serves as the Director of Infectious Diseases and as a Professor of Pediatrics. His expertise and research focus is on vaccines, immunology, and virology. 
    Dr. Offit is well known for being the co-creator of the rotavirus vaccine, RotaTeq, which was approved for inclusion in the U.S. vaccination schedule in 2006. For his work on the vaccine, he received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine and the Charles Mérieux Award from the National Foundation for Infectious Diseases. He was also honored by Bill and Melinda Gates during the launch of their Foundation’s Living Proof Project for global health.
    He has published over 160 papers in medical journals dealing with his work on the rotavirus vaccine and overall vaccine safety practices. He has also authored eight books on vaccines and how they are communicated about with the general public. 
    Previously, Dr. Paul Offit has been a member of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. He is a founding board member of the Autism Science Foundation and a board member of Every Child by Two. 
    Dr. Offit earned a B.S. from Tufts University in Boston, Massachusetts, and earned his M.D. from the University of Maryland, Baltimore. 
    Hosts:
    Terry Wilcox, Executive Director, Patients Rising
    Dr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.
    Kate Pecora, Field Correspondent 
    Links to other articles and videos to complement our interview with Dr. Paul Offit:
    Virology expert: coronavirus mortality ‘keeps coming down’ 
    Philly vaccine pioneer: We can’t rush a coronavirus vaccine |Q&A 
    Where to go for the latest information:
    CDC: COVID-19 What You Should Know
    Coronavirus.gov
    Resources from NIH
    Coronaviruses (National Institute of Allergy and Infectious Diseases)Coronavirus resources (National Library of Medicine)Coronavirus news and resources for global health researchers (Fogarty International Center)NIH clinical trial of remdesivir to treat COVID-19 begins (National Institute of Allergy and Infectious Diseases)Structural Biology Points Way to Coronavirus Vaccine (NIH Director's Blog)NIH Guidance on Travel and MeetingsWill my insurance cover a coronavirus test?
    Health Insurance Providers Respond to Caronavirus (COVID-19)
    Medicare: Is my test, item, or service covered?
    Who should be tested for Coronavirus?
    In addition to the advice that is continually updated by the CDC, you should check with your doctor about whether you need to be tested or when to take additional steps to protect yourself. 
    CDC: COVID-19 Information for Specific Groups
    Are my meds in short supply? 
    ASHP: Current Drug Shortages
    Data and studies:
    GIS COVID-19 Data
    Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
    Get a flu shot.
    Finally, we would be remiss if we did not urge our audience to get a flu shot and ensure that vaccinations for other diseases such as measles, pneumonia, etc., are up to date.
    There have been 32

    • 35 min
    Biosimilars: What You Need to Know

    Biosimilars: What You Need to Know

    Price: one the of largest barriers to medical treatment and accessible medicine. As many patients struggle to afford the high price tags at the pharmacy, there might soon be a solution. As more biosimilars enter the commercial market, some experts are claiming that they will actually lead to lower drug costs for patients everywhere. 
    In the second episode of the Patients Rising Podcast, we look into the relationship between biosimilars and drug prices, break down what exactly biosimilars are, and how they are changing the healthcare landscape. 
    Guest:
    Chad Pettit, Executive Director, Global Value Access and Policy, Amgen Biosimilars Business Unit, Thousand Oaks, California.
    Chad Pettit has worked with biotechnology company Amgen for nearly 20 years. In his current role as Executive Director, Mr. Pettit serves as a liaison with biopharmaceutical companies on biosimilar policy. He also focuses on introducing biosimilars to the market and working with policy to ensure commercialization leads to cost savings in all global regions. He works at the intersection of policy and biopharmaceutical medicine to facilitate greater accessibility and has an acute understanding of the impacts biosimilars have on the global health care market. Most recently, he has worked to construct a global market access launch strategy for Amgen’s 10 biosimilars. 
    Previously at Amgen, Mr. Pettit served on the U.S. Biosimilars industry trade group as the Amgen Board Member. 
    Mr. Pettit earned a B.S. in Chemical Engineering from the University of California, Davis, and an M.B.A. from the University of California, Los Angeles. 
    Hosts:
    Terry Wilcox, Executive Director, Patients Rising
    Dr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.
    Kate Pecora, Field Correspondent 
    Links: 
    Public Workshop: FDA/FTC Workshop on a Competitive Marketplace for Biosimilars
    Heimerdinger Foundation
    Ceres Community Project
    Patient’s Rising Concierge

    • 28 min
    How Insurers Double Dip with Copay Accumulators

    How Insurers Double Dip with Copay Accumulators

    The Centers for Medicare & Medicaid services are about to put a rule in place that allows insurers and pharmacy benefit managers to get paid TWICE for some of your prescriptions. 
    This policy is called “the copay accumulator,” and it allows insurers to accept payment for a drug without applying the payment to your deductible. 
    In the first episode of the Patients Rising Podcast, we discuss copay accumulators, and what patients need to know about them. We also talk about a looming deadline to comment on a proposed federal rule on the topic. 
    How to take action
    The deadline to comment on the rule regarding copay accumulators is 11:59 pm eastern standard time Monday, March 2nd, 2020.
    Let your voice be heard. Send your comments directly to Seema Verma, Administrator, Centers for Medicaid and Medicare Services (CMS).
    Tell her to honor your already high out of pocket costs, and to allow copay assistance to be applied to your deductible. 
    You can also do this directly from our website
    Guest:
    Carl Schmid, Executive Director, HIV + Hepatitis Policy Institute, Washington, D.C.
    Carl Schmid has been a national policy and advocacy leader in the HIV community for over 20 years.  He spent 16 years with The AIDS Institute, where he served as its Deputy Executive Director and led the Institute’s HIV and viral hepatitis federal policy work before the executive agencies and the Congress. In December 2019, he left The AIDS Institute to form the HIV + Hepatitis Policy Institute, which promotes quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions.
    Mr. Schmid helps lead the HIV and hepatitis communities’ advocacy efforts in Washington, D.C., to ensure domestic HIV and hepatitis programs, including the Ending the HIV Epidemic initiative, the Ryan White Program, CDC HIV and hepatitis prevention programs, and NIH AIDS Research, are based on sound public policy and receive full funding. 
    He has expertise in healthcare financing systems, including Medicaid and Medicare, and leads efforts to ensure that the Affordable Care Act meets the needs of people living with or at risk of HIV and hepatitis. As part of HIV + Hep’s work in advocating for people with HIV and hepatitis, Mr. Schmid works extensively with other patient and disease groups on collective efforts to ensure that patients, particularly those with chronic conditions, have access to quality and affordable healthcare, including prescription medications.
    Mr. Schmid served as a consumer representative to the National Association of Insurance Commissioners in 2018-19.  In July 2019, he was appointed to the PEPFAR Scientific Advisory Board.
    He was a member of the Presidential Advisory Council on HIV/AIDS from 2007-09 and chaired its Domestic Subcommittee.  In 2010, he was named by POZ magazine as one of the 100 most effective AIDS fighters and by Whitman-Walker Health as one of the 25 individuals who have played prominent roles in the fight against HIV in D.C. In 2016, he was named the Champion of the Year by the ADAP Advocacy Association. 
    Mr. Schmid earned a B.A. in Public Affairs and a M.B.A. in International Affairs from the George Washington University in Washington, D.C.
    Hosts:
    Terry Wilcox, Executive Director, Patients Rising
    Dr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.
    Kate Pecora, Field Correspondent 

    • 37 min

Customer Reviews

5.0 out of 5
9 Ratings

9 Ratings

EMHPDX ,

Straightforward information that’s easy to understand

I am appreciating this podcast and its timely updates about COVID-19, while also featuring multiple perspectives, including doctors, researchers, patients and advocates.

StarWarsFan5 ,

Insightful, honest, technical

If you want to talk healthcare, Terry, Bob and Kate, along with legit special guests inform and explore. Well worth a listen. Patients Rising is clearly fighting the good fight on behalf of patients, aka, all of us.

PatientTexas ,

Make the Patients Rising podcast a “must listen!”

Patients Rising’s tireless advocacy is outstanding! They are making a difference for all Americans. The podcast episodes will explain the complexities of topics with expert guests that will educate listeners so they too can also advocate for themselves, loved ones and/or other people !

Top Podcasts In Medicine